The Surprising Reason This Biotech Plummeted 69%
EyePoint Pharmaceuticals shares cratered following a late-stage trial setback for its flagship eye disease drug.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
EyePoint Pharmaceuticals investors faced steep losses as shares plummeted significantly following trial results. The Phase 3 LUGANO trial for the drug DURAVYU, targeting the age-related eye disease wet AMD, missed its primary endpoint. Financial analysts and market observers quickly reacted to the trial failure.
Cantor Fitzgerald downgraded EyePoint Pharmaceuticals to neutral. Reports from Barron's, Yahoo Finance, MarketBeat, and Investor's Business Daily noted that the stock was on track to hit 16-month lows, cratering between 69 percent and 71 percent in market value. Despite missing the primary endpoint, secondary data indicated that DURAVYU reduced the treatment burden.
Coverage does not yet specify the company's upcoming regulatory or clinical steps following the setback.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.
The reporting (8)
- EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD Yahoo Finance · 4h ago
- EyePoint's drug for age-related eye disease fails late-stage trial, shares tank Reuters · 4h ago
- EyePoint DURAVYU Phase 3 LUGANO Trial Misses Primary Endpoint as Secondary Data Show Reduced Treatment Burden Yahoo Finance · 4h ago
- Cantor Fitzgerald Downgrades Eyepoint Pharmaceuticals (NASDAQ:EYPT) to Neutral MarketBeat · 4h ago
- EyePoint's DURAVYU Cut Treatment Burden 42%—What It Missed Stock Titan · 4h ago
- EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction. barrons.com · 4h ago
- EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback finance.yahoo.com · 4h ago
- The Surprising Reason This Biotech Plummeted 69% Investor's Business Daily · 4h ago broke it first
Quick answers
What caused EyePoint stock to plummet?
The stock plummeted after the Phase 3 LUGANO trial for DURAVYU missed its primary endpoint.
What disease was the trial targeting?
The trial targeted wet age-related macular degeneration (wet AMD).
How did financial institutions react?
Cantor Fitzgerald downgraded EyePoint Pharmaceuticals to neutral following the trial failure.
People, places & organizations
Topics
Related trends
Micron Stock Is Falling Even Harder Today and It’s an Ominous Sign
Micron Technology shares are experiencing a sharp decline as a broader semiconductor sell-off intensifies, fueling debate over the company's valuation.
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics shares are plummeting after FDA staff disputed the company's claims of Phase 3 success for its DMD cell therapy.
Why another shocking Meta capex number may keep the stock underwater
Meta stock has fallen for seven consecutive days as investors weigh concerns over high capital expenditures ahead of the upcoming Q2 earnings report.
Wall St climbs after US, Iran pause conflict; focus on Fed, earnings
U.S. stocks surge as a pause in U.S.-Iran tensions lifts markets, but a Fed decision this week keeps traders on edge.
Palantir: Rule Of 145% May Fail (Rating Downgrade)
Palantir faces conflicting market signals as a potential rating downgrade clashes with bullish growth estimates and rally predictions.
Stocks mixed as oil prices pause climb but yields hover near highs
Investors are weighing a potential threat to the stock rally as oil prices reach $100 and bond yields remain near highs.